TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss

Phase 1

• Conditions: Safety Issues; Efficacy, Self
• Interventions: Drug: TQB3525

• Registration Number: NCT04690725
• Lead Sponsor: Peking University People's Hospital

Brief Summary

The PI3K, protein kinase B (AKT), and mTOR signaling network promotes cell growth, survival, metabolism, and motility, but becomes a critical oncogenic driver under aberrant conditions that control the tumor microenvironment and angiogenesis. The PI3K-AKT-mTOR axis is the most frequently deregulated signaling pathway in primary osteosarcoma and other bone tumors. PI3Ka has high rates of 25-50% activating mutations associated with tumor formation in osteosarcoma. Other causes of pathway hyperactivation include loss of function of the tumor suppressor PTEN, gain-of-function mutations in AKT and PDK1, or upregulation of receptor tyrosine kinases. TQB3525 is an orally bioavailable, potent, dual catalytic site inhibitor of PI3Ka and PI3Kd. Tumor growth inhibition has been demonstrated in multiple xenograft osteosarcoma models with PI3K-mutant, PTEN-null cell lines. The investigators try to investigate TQB3525 in primary osteosarcoma and other bone tumors for its safety, tolerability, dose-limiting toxicities (DLT), MTD and antitumor efficacy.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-01
• Status Verified: 2020-12
• Study First Submitted: 2020-12-25
• Study First Submitted QC: 2020-12-29
• Last Update Submitted: 2020-12-29
• Study First Posted: 2020-12-31
• Last Update Posted: 2020-12-31
• Primary Completion: 2022-01-01
• Study Completion: 2022-06-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• progression upon first-line chemotherapy;
• with target lesions according to RECIST 1.1;
• geno-profiling with PI3KA mutations or PTEN loss;
• ECOG PS status 0 or 1 with a life expectancy >3 months;
• adequate renal, hepatic, and hematopoietic function;

Exclusion Criteria

• been previously exposed to other TKIs;
• had central nervous system metastasis;
• had other kinds of malignant tumors at the same time;
• had cardiac insufficiency or arrhythmia;
• had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++, and so on;
• had pleural or peritoneal effusion that needed to be handled by surgical treatment;
• had other infections or wounds;
• pregnant or breastfeeding.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TQB3525 arm	TQB3525	3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD

Primary Outcome Measures

Name	Time	Method
toxicity profiles	6 months	according to CTCAE 5.0

Secondary Outcome Measures

Name	Time	Method
progression free survival	6 months	from starting treatment to progression/death
overall survival	2 years	from starting treatment to death

Trial Locations

Locations (1)

Peking University Shougang Hospital; 🇨🇳 Beijing, China